CStone Pharmaceuticals
HKEX:2616
Income Statement
Earnings Waterfall
CStone Pharmaceuticals
Revenue
|
463.8m
CNY
|
Cost of Revenue
|
-159.5m
CNY
|
Gross Profit
|
304.3m
CNY
|
Operating Expenses
|
-812.5m
CNY
|
Operating Income
|
-508.2m
CNY
|
Other Expenses
|
141m
CNY
|
Net Income
|
-367.2m
CNY
|
Income Statement
CStone Pharmaceuticals
Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1 039
N/A
|
1 118
+8%
|
244
-78%
|
426
+75%
|
481
+13%
|
481
0%
|
464
-4%
|
|
Gross Profit | ||||||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
(241)
|
(273)
|
(107)
|
(168)
|
(203)
|
(218)
|
(160)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
797
N/A
|
846
+6%
|
137
-84%
|
258
+88%
|
278
+8%
|
263
-6%
|
304
+16%
|
|
Operating Income | ||||||||||||
Operating Expenses |
(1 017)
|
(1 018)
|
(1 713)
|
(1 892)
|
(1 860)
|
(1 931)
|
(1 930)
|
(1 679)
|
(1 158)
|
(1 029)
|
(812)
|
|
Selling, General & Administrative |
(191)
|
(322)
|
(341)
|
(363)
|
(485)
|
(583)
|
(661)
|
(655)
|
(576)
|
(516)
|
(382)
|
|
Research & Development |
(850)
|
0
|
(1 396)
|
(1 556)
|
(1 405)
|
(1 373)
|
(1 305)
|
(1 059)
|
(591)
|
(529)
|
(501)
|
|
Other Operating Expenses |
24
|
(697)
|
24
|
27
|
30
|
25
|
36
|
35
|
9
|
15
|
71
|
|
Operating Income |
(1 017)
N/A
|
(1 018)
0%
|
(1 713)
-68%
|
(1 892)
-10%
|
(1 062)
+44%
|
(1 086)
-2%
|
(1 793)
-65%
|
(1 421)
+21%
|
(880)
+38%
|
(767)
+13%
|
(508)
+34%
|
|
Pre-Tax Income | ||||||||||||
Interest Income Expense |
(746)
|
(1 218)
|
(578)
|
148
|
(159)
|
(238)
|
(126)
|
(86)
|
1
|
22
|
(12)
|
|
Non-Reccuring Items |
(30)
|
(48)
|
(18)
|
(0)
|
0
|
0
|
(1)
|
0
|
(23)
|
(6)
|
152
|
|
Pre-Tax Income |
(1 793)
N/A
|
(2 285)
-27%
|
(2 308)
-1%
|
(1 744)
+24%
|
(1 221)
+30%
|
(1 324)
-8%
|
(1 920)
-45%
|
(1 508)
+21%
|
(903)
+40%
|
(750)
+17%
|
(367)
+51%
|
|
Net Income | ||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(1 793)
|
(2 285)
|
(2 308)
|
(1 744)
|
(1 221)
|
(1 324)
|
(1 920)
|
(1 508)
|
(903)
|
(750)
|
(367)
|
|
Income to Minority Interest |
48
|
21
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Net Income (Common) |
(470)
N/A
|
(1 246)
-165%
|
(2 069)
-66%
|
(1 744)
+16%
|
(1 221)
+30%
|
(1 324)
-8%
|
(1 920)
-45%
|
(1 508)
+21%
|
(903)
+40%
|
(750)
+17%
|
(367)
+51%
|
|
EPS (Diluted) |
-2.79
N/A
|
-1.68
+40%
|
-2.39
-42%
|
-1.74
+27%
|
-1.17
+33%
|
-1.14
+3%
|
-1.65
-45%
|
-1.28
+22%
|
-0.77
+40%
|
-0.59
+23%
|
-0.29
+51%
|